<DOC>
	<DOCNO>NCT00754494</DOCNO>
	<brief_summary>This randomized phase II trial study well erlotinib hydrochloride work treat patient stage I-III colorectal cancer adenoma . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Erlotinib hydrochloride may also stop tumor grow come back</brief_summary>
	<brief_title>Erlotinib Hydrochloride Treating Patients With Stage I-III Colorectal Cancer Adenoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To test hypothesis erlotinib ( erlotinib hydrochloride ) dose low 25 mg decrease aberrant crypt focus ( ACF ) phosphorylated extracellular signal-regulated kinase ( pERK ) level baseline ( pre ) post erlotinib treatment . SECONDARY OBJECTIVES : I . To test hypothesis additional epidermal growth factor ( EGF ) inducible biomarkers decrease baseline ( pre ) post treatment erlotinib 25 mg , 50 mg 100 mg orally ( PO ) daily ( QD ) therapy . II . To determine mean decrease baseline ACF : normal mucosa pERK ratio pre post 8-30 day erlotinib . III . To determine erlotinib concentration plasma colorectal tissue 25 mg , 50 mg 100 mg dos 8-30 day therapy . IV . To determine incidence rash , diarrhea side effect low dose erlotinib . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive 100 mg erlotinib hydrochloride PO two 25 mg placebo PO QD . ARM II : Patients receive 50 mg erlotinib hydrochloride PO one 100 mg placebo PO QD . ARM III : Patients receive 25 mg erlotinib hydrochloride PO one 100 mg placebo one 25 mg placebo PO QD . In arm , treatment continue 8-30 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 9 week .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyps</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Participants one follow criterion eligible participate : History Stage IIII colorectal cancer , treat past 6 month anticipate treatment next 3 month Adenoma ≥ 1 cm size 3 adenoma ( size ) remove one colonoscopy within past 6 year Sessile serrate adenoma ≥ 5 mm size Adenoma ( size ) villous feature ( villous , tubulovillous ) Adenoma ( size ) high grade dysplasia Participants eligible randomization treatment phase trial find ≥ 4 ACFs either baseline colonoscopy baseline flexible sigmoidoscopy Blood test screen meet follow criterion : WBC &gt; 3000/mm^3 Platelets &gt; 100,000/mm^3 Hemoglobin &gt; 10g/dl Plasma creatinine &lt; 1.6mg/dl Total bilirubin &lt; 1.5 x upper limit normal Serum ALT &lt; 1.5 x upper limit normal Serum AST &lt; 1.5 x upper limit normal ECOG performance status 01 Women childbearing potential men take study drug must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Ability understand , well sign write informed consent document If woman childbearing potential , must negative pregnancy test prior study entry ; woman become pregnant suspect pregnant participating study , inform study physician immediately History Inflammatory Bowel Disease ( IBD ) History interstitial lung disease chronic lung disease Smoking within past 3 month Increased bleed risk rectal biopsy ( Patients receive aspirin plavix enrol ) Patients receive warfarin coumadin Uncontrollable diarrhea cause Patients , include rectal cancer patient , receive prior radiation rectum pelvis Participants take known significant CYP 3A4 inducer inhibitor ; know significant inducers/inhibitors include : amprenavir , aprepitant , atazanavir , carbamazepine , clarithromycin , conivaptan , diltiazem , darunavir/ritonavir , dronedarone , erythromycin , fluconazole , fosamprenavir , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , phenytoin , posaconazole , rifampin , ritonavir , St. John 's wort , saquinavir , telithromycin , tipranavir/ritonavir , verapamil , voriconazole Women pregnant breastfeed Active keratoconjunctivitis , corneal surgery past three week Any medical psychosocial condition could jeopardize subject 's participation compliance study Participants take investigational pharmaceutical agent Previous history sensitivity erlotinib , Iressa , Erbitux , rash uncontrollable topical steroid and/or antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>